Siren Song Of Lupus Has Left A Legacy Of Failed Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The five-decade drought in FDA approvals of lupus therapies – broken by Human Genome Sciences Inc.'s recent launch of Benlysta – featured a steady stream of drug developers that were not dissuaded by the legacy of trial failures and shifting regulatory standards that marked the field, only to join the ranks of clinical failures in lupus.
You may also be interested in...
FDA’s Benlysta Approval: A Lesson In Overcoming Unvalidated Endpoints
A novel composite primary endpoint created by Human Genome Sciences with FDA’s blessing helped Benlysta (belimumab) obtain approval for lupus – one of contemporary drug development’s most challenging indications – despite the absence of a standard disease outcome measure.
FDA’s Benlysta Approval: A Lesson In Overcoming Unvalidated Endpoints
A novel composite primary endpoint created by Human Genome Sciences with FDA’s blessing helped Benlysta (belimumab) obtain approval for lupus – one of contemporary drug development’s most challenging indications – despite the absence of a standard disease outcome measure.
FDA Guidances On Lupus Drug Development Call For Superiority Trials
For development of drugs for either 1systemic lupus erythematosus or 2lupus nephritis, the gold standard study design is a randomized superiority trial, using either placebo or active control with the investigational therapy as an add-on to standard of care, according to a pair of final guidances released by FDA June 21